Navigation Links
Patency On Two Drugs From Merck & Pfizer’s To Expire Soo

t to improve their new-drug pipelines.

Any market analysts though believe that with the loss of patency, Zocor might threaten the sales of Lipitor, which is another anti cholesterol drug from Pfizer as there may now be stiff competition from the generic bands of Zocor. Reports have also shown that Lipitor was the world's top-selling drug with a estimated revenue of $12.2 billion in the 2005 sales.

Pfizer, and also certain analysts, have insisted that Lipitor is not alike with the competing products like Zocor. Officials from Pfizer have stated that they are looking to create market space by testing Lipitor that has been successful in lowering LDL or "bad" cholesterol, in combination with the experimental drug torcetrapib, which has shown to raise HDL, or "good" cholesterol. Many experts believe that if the tests are successful and the drug gets a FDA-approval then this potential combination could add billions of dollars in revenue in potential sales.

'"/>




Page: 1 2

Related medicine news :

1. Drug-Eluting Stents Ensure Patency Of The Saphenous Vein Grafts
2. Lean Protein Could Be Key to Obesity Drugs
3. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
4. Nasal Spray Could Take Drugs Direct to Brain.
5. Emphasis to ban Drugs ads by Doctors
6. Osteoporosis Drugs: right time to take-off
7. Drugs disrupt formation of blood vessels
8. Drugs to stop burgeon of HIV
9. Misleading Advertisements for Prescription Drugs
10. Drugs For Anthrax May Interfere With Oral Contraceptives
11. Over-The-Counter Drugs May Prevent Alzheimers
Post Your Comments:
Breaking Medicine Technology:China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 2Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 3Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 4Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 5New Productivity Suite From Varian Inc Increases Throughput for NMR Laboratories 14169 1New Productivity Suite From Varian Inc Increases Throughput for NMR Laboratories 14169 2New Productivity Suite From Varian Inc Increases Throughput for NMR Laboratories 14169 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 1DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 2DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 4DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 1Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 3Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 4Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 5Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 7Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 8